Trials / Terminated
TerminatedNCT04300881
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)
Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists): The TOTEM Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Wagner Macula & Retina Center · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Evaluate the efficacy of eplerenone as an adjunctive treatment to intravitreal ocriplasmin for subretinal fluid in comparison to a control group of only receiving intravitreal ocriplasmin in patients with symptomatic vitreomacular adhesion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone | Following intravitreal ocriplasmin therapy |
Timeline
- Start date
- 2019-10-04
- Primary completion
- 2021-01-05
- Completion
- 2021-01-05
- First posted
- 2020-03-09
- Last updated
- 2021-01-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04300881. Inclusion in this directory is not an endorsement.